CA2446929C - Orally administering parathyroid hormone and calcitonin - Google Patents

Orally administering parathyroid hormone and calcitonin Download PDF

Info

Publication number
CA2446929C
CA2446929C CA2446929A CA2446929A CA2446929C CA 2446929 C CA2446929 C CA 2446929C CA 2446929 A CA2446929 A CA 2446929A CA 2446929 A CA2446929 A CA 2446929A CA 2446929 C CA2446929 C CA 2446929C
Authority
CA
Canada
Prior art keywords
pth
calcitonin
pharmaceutical composition
composition according
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2446929A
Other languages
French (fr)
Other versions
CA2446929A1 (en
Inventor
Joseph Ault
Moise Azria
Simon David Bateman
James F. Mcleod
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23136525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2446929(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA2446929A1 publication Critical patent/CA2446929A1/en
Application granted granted Critical
Publication of CA2446929C publication Critical patent/CA2446929C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

A method for orally administering a parathyroid hormone, PTH, comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of a calcitonin. The method according to the invention allows for the oral administration of PTH without the hypercalcemia, hypercalcuria and nephrolithiasis side effects.

Description

Orally Administering Parathyroid Hormone and Calcitonin Background of the Invention 1. Field of the Invention The present invention relates to the oral delivery of parathyroid hormone (PTH).
More particularly, the invention is directed to the use of calcitonin in combination with PTH
for the oral administration of PTH.
2. Description of the Related Art PTH studies done in animals and humans with PTH, PTH-related peptides, and PTH
analogs have demonstrated its usefulness in increasing bone formation and bone resorption and have prompted interest in its use for the treatment of osteoporosis and related bone disorders. However, the clinical utility of PTH is limited by the occurrence of hypercalcemia, hypercalcuria and nephrolithiasis. The occurrence of these potentially toxic side effects and alterations in calcium metabolism have remained an obstacle to exploiting the benefits of higher dosages of PTH and have required, for safety concerns, that plasma concentrations of the PTH remain within a narrow band. If the hypercalcemic effects, largely mediated by osteoclasts, could be separated from the bone formative effects, largely mediated by osteoblasts, then the therapeutic window for oral PTH therapy could be increased. In contrast to PTH, calcitonins reduce serum calcium concentrations by interacting directly with osteoclasts resulting in reduction in the bone resorptive surface area by osteoclasts and reduction in net bone resorption. Due to a decrease in plasma calcium concentration there is a corresponding decrease in urinary calcium concentrations, a known risk factor for nephrolithiasis. The present invention describes a method for orally administering PTH which broadens the therapeutic window for PTH administration and allows for the oral administration of greater PTH dosages without the potentially toxic hypercalcemic side effects.

Summary of the Invention Accordingly, the present invention is directed to a method for orally administering an effective dose of PTH comprising orally co-administering to a patient in need of PTH an effective amount of a PTH and an effective amount of a calcitonin.

Administration of PTH to primates results in increased plasma concentrations of serum parathyroid hormone and serum calcium. Conversely the administration of salmon calcitonin (sCT) to primates results is an increase in serum sCT
concentrations and a reduction in serum calcium. It has now been found that the oral administration of a combination of PTH and calcitonin, while resulting in similar PTH and calcitonin plasma concentration levels as those attained upon administrations of each agent alone; quite surprisingly results in reduction of serum calcium concentrations to the level observed with calcitonin alone. In effect, the calcitonin negates the hypercalcemic effect of the PTH while attaining the same reduction in serum calcium obtained when calcitonin is administered alone, in the absence of PTH. Administering calcitonin with PTH therapy allows the additional therapeutic effects of the presently precluded PTH doses without the hypercalcemic side effects. Additionally, the calcitonin provides an analgesic effect which is useful in off-setting the bone pain usually associated with administration of PTH.

The invention is also directed to a method of stimulating new bone formation comprising orally administering to a patient in need of new bone formation a therapeutically effective amount of a PTH and a therapeutically effective amount of a calcitonin.
In a further embodiment, the invention is directed to a method of treatment or prevention of osteoporosis comprising orally administering to a patient in need of said treatment or prevention a therapeutically effective amount of a PTH and a therapeutically effective amount of a calcitonin.
The invention is also directed to a composition suitable for oral delivery comprising a PTH and a calcitonin, e.g. for simultaneous, concurrent or sequential administration of the PTH and calcitonin.
The invention is further directed to use of PTH and calcitonin for the preparation of an orally administrable medicament for the stimulation of new bone formation, e.g. for simultaneous, concurrent or sequential oral administration of the PTH and calcitonin.
The invention is yet further directed to a kit for the stimulation of new bone formation comprising PTH and calcitonin suitable for oral administration together with instructions for the oral administration thereof, e.g. for simultaneous, concurrent or sequential oral administration of the PTH and calcitonin.

-2a-According to one embodiment of the present invention, there is provided a pharmaceutical composition for oral administration comprising a PTH, a calcitonin and a delivery agent, said delivery agent being a compound of formula 1:

~ N' I I Y

H 0 1, wherein R1, R2, R3, and R4 are independently hydrogen, -OH, -NR6R7, halogen, C1-C4alkyl, or C1-C4alkoxy; R5 is a substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted C2-C16alkenylene, substituted or unsubstituted C1-C12alkyl(arylene), or substituted or unsubstituted aryl(C1-C12alkylene);
and R6 and R7 are independently.

According to another embodiment of the present invention, there is provided use of the pharmaceutical composition as described herein for the preparation of an orally administrable medicament for the stimulation of bone formation.

According to still another embodiment of the present invention, there is provided use of the pharmaceutical composition as described herein for the preparation of an orally administrable medicament for treatment of osteoporosis.

According to yet another embodiment of the present invention, there is provided use of the pharmaceutical composition as described herein for the stimulation of bone formation.

According to a further embodiment of the present invention, there is provided use of the pharmaceutical composition as described herein for treatment of osteoporosis.

Further features and advantages of the invention will become apparent from the following detailed description of the invention.
Detailed Description of the Invention The parathyroid hormone or PTH can be the full length, 84 amino acid form of parathyroid hormone, e.g. the human form, hPTH (1-84), or any polypeptide, protein, protein fragment, or modified fragment, i.e. PTH-related peptides and PTH
analogs, capable of mimicing the activity of hPTH (1-84) in controlling calcium and phosphate metabolism to build bone in the human body. The PTH fragments will generally incorporate at least the first 28 N-terminal residue and include PTH (1-28), PTH (1-31), PTH (1-34), PTH
(1-37), PTH (1-38) and PTH (1-41) or analogues thereof, e.g. PTS893. The PTH
can be a single PTH or any combination of two or more PTHs. These parathyroid hormones are commercially available or can be obtained recombinantly, by peptide synthesis, or by extraction from human fluid by methods well established in the art.
The calcitonin for use in the instant invention can be any calcitonin, including natural, synthetic or recombinant sources thereof, as well as calcitonin derivatives such as 1,7-Asn-eel calcitonin. Various calcitonins, including salmon, pig and eel calcitonin are commercially available and commonly employed for the treatment of e.g. Paget's disease, hypercalcemia of malignancy and osteoporosis. The calcitonin can comprise a single calcitonin or any combination of two or more calcitonins. The preferred calcitonin is synthetic salmon calcitonin.
The calcitonins are commercially available or may be obtained by known methods.
The amount of PTH to be administered is generally an amount effective to stimulate new bone formation i.e. a therapeutically effective amount. This amount will necessarily vary with the age, size, sex and condition of the subject to be treated, the nature and severity of the disorder to be treated and the like. However, the amount can be less than that amount when a plurality of the compositions are to be administered, i.e., the total effective amount can be administered in cumulative dosage units. The amount of PTH can also be more than the effective amount when the composition provides sustained release of the pharmacologically active agent. The total amount of PTH to be used can be determined by methods known to those skilled in the art. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.001 gg/kg to about 10 mg/kg animal body weight, preferably 1 gg/kg to about 6 gg/kg body weight.
The appropriate dosage of calcitonin to be administered will, of course, vary depending upon, for example, the amount of PTH to be administered and the severity of the condition being treated. However, in general, satisfactory results will be obtained systemically at daily dosages of from about 0.5 g/kg to about 10 fi.g/kg animal body weight, preferably 1 g/kg to about 6 pg/kg body weight.
The oral administration can be accomplished regularly, e.g. once or more on a daily or weekly basis; intermittently, e.g. irregularly during a day or week; or cyclically, e.g. regularly for a period of days or weeks followed by a period without administration.
The co-administration of PTH and calcitonin includes simultaneous, concurrent, or sequential administration of the two compounds. Simultaneous administration means administration of the two compounds in a single dosage form; concurrent administration means administration of the two compounds at about the same time but in separate dosage forms; and , sequential administration means administration of one of the compounds, after which the other is administered. Sequential administration may also take the form of simultaneous or concurrent administration of the two compounds, followed by cessation of the simultaneous or concurrent administration and then continued administration of one of the two compounds alone.
The oral administration of the PTH and calcitonin according to the instant invention can be accomplished in any known manner, e_g. as a liquid or solid dosage forms.
The liquid dosage forms include solution, emulsions, suspensions, syrups and elixirs.
In addition to the PTH and/or calcitonin, the liquid formulations may also include inert excipients commonly used in the art such as, solubilizing agents such as ethanol; oils such as cottonseed, castor and sesame oils; wetting agents; emulsifying agents;
suspending agents; sweeteners; flavorings; and solvent such as water.
The solid dosage forms include capsules, soft-gel capsules, tablets, caplets, powders, granules or other solid oral dosage forms, all of which can be prepared by methods well known in the art. In addition to the PTH and/or calcitonin, these solid dosage forms generally include a pharmaceutically acceptable delivery agent for the PTH and/or calcitonin.
Suitable delivery agents are any one of the 123 modified amino acids disclosed in U.S. Patent No. 5,866,536 or anyone of the 193 modified amino acids described in US
Patent No. 5,773,647 or any combination thereof. The contents of the aforementioned US
Patent Nos. 5,773,647 and 5,866,536.
In addition, the delivery agent can be the disodium salt of any of the aforementioned modified amino acids as well as ethanol solvates and hydrates thereof.
Suitable compounds include compounds of the following formula I
I Y
H O
R OH
R
Formula I
wherein R1, R2, R3, and R4 are independently hydrogen, -OH, -NR6R7, halogen, C,-C4alkyl, or G1-C4alkoxy;
R5 is a substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted C2-C16alkenylene, substituted or unsubstituted C,-C72alkyl(arylene), or substituted or unsubstituted aryl(C'1-Ct2alkylene); and R6 and R7 are independently hydrogen, oxygen, or C1-C4 alkyl; and hydrates and alcohol solvates thereof. The compounds of formula I as well as their disodium salts and alcohol solvates and hydrates thereof are described in WO 00/059863, along with methods for preparing them.
The preferred delivery agents are N-(5-chlorosalicyloyl)-8-aminocapryfic acid (5-CNAC), N-(10-f2-hydroxybenzoyljamino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyljamino)caprylic acid (SNAC)and their monosodium and disodium salts, ethanol solvates of'their sodium salts and the monohydrates of their sodium salts and any combinations thereof. The most preferred delivery agent is the disodium salt of 5-CNAC
and the monohydrate thereof.
The pharmaceutical compositions of the present invention typically contain a delivery effective amount of one or more of the delivery agents, i.e. an amount sufficient to deliver the PTH and/or calcitonin for the desired effect. Generally, the delivery agent is present in an amount of 2.5% to 99.4% by weight, more preferably 25% to 50% by weight of the total composition.
The compositions may additionally comprise additives in amounts customarily employed including, but not limited to, a pH adjuster, a preservative, a flavorant, a taste-masking agent, a fragrance, a humectant, a tonicifier, a colorant, a surfactant, a plasticizer, a lubricant such as magnesium stearate, a flow aid, a compression aid, a solubilizer, an TM
excipient, a diluent such as microcrystalline cellulose, e.g. Avicel PH 102 supplied by FMC
corporation, or any combination thereof. Other additives may include phosphate buffer salts, citric acid, glycols, and other dispersing agents.
The composition may also include one or more enzyme inhibitors, such as actinonin TM
or epiactinonin and derivatives thereof; aprotinin,Trasylol and Bowman-Birk inhibitor.
Further, a transport inhibitor, i.e. a p-glycoprotein such as Ketoprofin, may be present in the compositions of the present invention.
The solid pharmaceutical compositions of the instant invention can be prepared by conventional methods e.g. by blending a mixture of the active agent or active agents, the delivery agent, and any other ingredients, kneading, and filling into capsules or, instead of filling into capsules, molding followed by further tableting or compression-molding to give tablets. In addition, a solid dispersion may be formed by known methods followed by further processing to form a tablet or capsule.
Preferably, the ingredients in the pharmaceutical compositions of the instant invention are homogeneously or uniformly mixed throughout the solid dosage form.
The oral administration of the present invention may be to any animal in need thereof, including, but not limited to, mammals, such as rodents, cows, pigs, dogs, cats, and primates, particularly humans.
The following examples serve to further illustrate the invention.

The following capsules are prepared as follows:
Capsules prepared from 400 mg 5-CNAC disodium salt/800 mcg sCT/800 mcg PTH
(Capsule 1A) Capsules prepared from 400 mg 5-CNAC disodium salt/800 mcg PTH (Capsule 1 B) Capsules prepared from 400 mg 5-CNAC disodium salt/800 mcg sCT (Capsule 1C) Capsules prepared from 800 mcg PTH (Capsule 1 D) The PTH is PTH fragment 1-34, commercially available. The sCT is salmon calcitonin. The capsules are all prepared as dry blends by weighing out the individual components blending them together to make a homogeneous mix and then hand filling 400 mg of the mix into each capsule. For the PTH only capsules, the PTH is weighed out and 400 mg placed directly into each capsule.
Primate Administration The capsules prepared in Example 1 are administered to Rhesus monkeys as follows: four monkeys in a group are each dosed with one capsule prepared as in Example 1 as follows:
The Rhesus monkeys fast overnight prior to dosing and are restrained in chairs fully conscious, for the duration of the study period. The capsules are administered via a gavage tube followed by 10 mL of water.
Blood samples are collected at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, and 6 hours after administration. Plasma salmon calcitonin and plasma PTH are determined by radioimmunoassay. The primate plasma salmon calcitonin (sCT) and PTH results from each group of monkeys are averaged and the maximum mean plasma calcitonin are calculated and reported in Tables 1-5 SALMON CALCITONIN and PTH
SCT PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO THE
RHESUS MONKEY
Dose : 1 Capsule 1 A
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6 Mean 0 284 389 389 429 411 370 143 66 19 11 LLOQ = 11 pg/mL, concentrations below LLOQ were set to zero.

SALMON CALCITONIN and PTH
PTH PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO THE
RHESUS MONKEY
Dose : 1 Capsule 1 A
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6 Mean 0 99 160 156 168 153 119 53 25 7 0 SEM 0 37, 65 49, 57 52 47 18 8 7 0 LLOQ = 25 pg/mL, concentrations below LLOQ were set to zero.
SALMON CALCITONIN
CALCIUM PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO
THE RHESUS MONKEY
Dose : 1 Capsule 1C
Animal Time [hours]
no. 0 1 2 3 4 5 6 R944 0.00 -3.08 -6.54 -8.99 -13.89 -12.88 -13.75 S966 0.00 -9.74 -17.30 -23.43 -24.86 -31.27 -30.70 S945 0.00 -2.36 -2.81 -7.24 -9.75 -11.23 -11.96 S961 0.00 -7.00 -12.92 -13.06 -18.69 -18.27 -23.91 CP943 0.00 -1.54 -7.97 -10.36 -17.23 -13.50 -12.60 S9510 0.00 -9.16 -12.05 -15.07 -20.16 -22.49 -26.07 Mean 0.00 -5.48 -9.93 -13.02 -17.43 -18.27 -19.83 SD 0.00 3.61 5.17 5.82 5.21 7.59 8.06 SEM 0.00 1.47 2.11 2.38 2.13 3.10 3.29 PTH
PTH PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO THE
RHESUS MONKEY
Dose : 1 Capsule 1 B
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6 Mean 0 105 262 482 809 206 94 17 0 0 0 _-__ TABLE 5 PTH
PTH PLASMA CONCENTRATIONS (pg/mL) AFTER ORAL ADMINISTRATION TO THE
RHESUS MONKEY
Dose : 1 Capsule 1 D
Animal Time [hours]
no. 0 0.25 0.50 0.75 1 1.5 2 3 4 5 6 S982 i 0 0 0 0 0 0 0 0 0 0 0 Mean 0 0 0 0 0 0 0 0 0 0 0 LLOQ = 25 pg/mL, concentrations below LLOQ were set to zero.

As can be seen from the data in Tables 1-5, the sCT and PTH plasma levels are essentially the same whether the compounds are administered separately or together.
However, the oral administration of a combination of PTH and calcitonin, while resulting in similar PTH
and calcitonin plasma concentration levels as those attained upon administrations of each agent alone; quite surprisingly results in reduction of serum calcium concentrations to the level observed with calcitonin alone.

Claims (11)

CLAIMS:
1. A pharmaceutical composition for oral administration comprising a PTH, a calcitonin and a delivery agent, said delivery agent being a compound of formula 1:
wherein R1, R2, R3, and R4 are independently hydrogen, -OH, -NR6R7, halogen, C1-C4alkyl, or C1-C4alkoxy; R5 is a substituted or unsubstituted C2-C16alkylene, substituted or unsubstituted C1-C16alkenylene, substituted or unsubstituted C1-C12alkyl(arylene), or substituted or unsubstituted aryl(C1-C12alkylene);
and R6 and R7 are independently hydrogen, oxygen or C1-C4 alkyl.
2. The pharmaceutical composition according to claim 1 wherein the PTH is a human form of PTH.
3. The pharmaceutical composition according to claim 1 wherein the PTH is the human PTH 1-34.
4. The pharmaceutical composition according to any one of claims 1 to 3 wherein the calcitonin is salmon calcitonin.
5. The pharmaceutical composition according to any one of claims 1 to 4 wherein the delivery agent is N-(5-chlorosalicyloyl)-8-aminocaprylic acid, N-(10-[2-hydroxybenzoyl]amino)decanoic acid, N-(8-[2-hydroxybenzoyl]amino)-caprylic acid, or a monosodium or disodium salt thereof, or any combination thereof.
6. Use of the pharmaceutical composition according to any one of claims 1 to 5 for the preparation of an orally administrable medicament for the stimulation of bone formation.
7. Use of the pharmaceutical composition according to any one of claims 1 to 5 for the preparation of an orally administrable medicament for treatment of osteoporosis.
8. Use of the pharmaceutical composition according to any one of claims 1 to 5 for the stimulation of bone formation.
9. Use of the pharmaceutical composition according to any one of claims 1 to 5 for treatment of osteoporosis.
10. The pharmaceutical composition according to any one of claims 1 to 5 for use in the stimulation of bone formation.
11. The pharmaceutical composition according to any one of claims 1 to 5 for use in the treatment of osteoporosis.
CA2446929A 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin Expired - Fee Related CA2446929C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29516901P 2001-06-01 2001-06-01
US60/295,169 2001-06-01
PCT/EP2002/006017 WO2002098453A2 (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Publications (2)

Publication Number Publication Date
CA2446929A1 CA2446929A1 (en) 2002-12-12
CA2446929C true CA2446929C (en) 2013-04-09

Family

ID=23136525

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2446929A Expired - Fee Related CA2446929C (en) 2001-06-01 2002-05-31 Orally administering parathyroid hormone and calcitonin

Country Status (25)

Country Link
US (2) US20040186050A1 (en)
EP (1) EP1397156B1 (en)
JP (2) JP5073153B2 (en)
KR (3) KR20040007617A (en)
CN (2) CN1512892A (en)
AT (1) ATE356631T1 (en)
AU (2) AU2002344371B2 (en)
BR (1) BRPI0209748B1 (en)
CA (1) CA2446929C (en)
CO (1) CO5540323A2 (en)
CZ (1) CZ307145B6 (en)
DE (1) DE60218842T2 (en)
EC (1) ECSP034858A (en)
ES (1) ES2282436T3 (en)
HU (1) HU229613B1 (en)
IL (2) IL158777A0 (en)
MX (1) MXPA03011027A (en)
NO (1) NO330093B1 (en)
NZ (1) NZ529439A (en)
PL (1) PL211976B1 (en)
PT (1) PT1397156E (en)
RU (1) RU2300392C2 (en)
SK (1) SK287697B6 (en)
WO (1) WO2002098453A2 (en)
ZA (1) ZA200308625B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011027A (en) 2001-06-01 2004-03-19 Novartis Ag Orally administering parathyroid hormone and calcitonin.
RU2322256C2 (en) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac as agent for oral delivery of parathyroid hormone fragments
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20100241A1 (en) 2005-09-19 2010-04-16 Emisphere Tech Inc CRYSTALLINE FORMS OF THE DI-SODIUM SALT OF N- (5-CHLOROSALICILOYL) -8-AMINOCAPRYLIC ACID
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
WO2007059470A2 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
KR101432313B1 (en) * 2005-11-17 2014-08-20 노파르티스 아게 Pharmaceutical composition
PL2215047T3 (en) 2007-11-02 2014-05-30 Emisphere Tech Inc Method of treating vitamin b12 deficiency
EP3741359A1 (en) * 2008-08-18 2020-11-25 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CN104857505A (en) * 2008-08-18 2015-08-26 安特拉贝欧有限公司 Methods And Compositions For Oral Administration Of Proteins
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN104800564A (en) * 2015-04-02 2015-07-29 中国人民解放军济南军区总医院 Traditional Chinese medicine composition for treating blood stasis and lusterless face type hypoparathyroidism
KR101796604B1 (en) * 2016-08-30 2017-11-10 목포대학교 산학협력단 Oral dosage form of parathyroid hormone comprising the gastrointestinal absorption enhancer
KR102115353B1 (en) * 2019-05-17 2020-05-26 주식회사 노브메타파마 Composition comprising chp (cyclo-his pro) and pth for preventing, improving or treating of bone loss related disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH08507070A (en) * 1993-02-22 1996-07-30 アルザ・コーポレーション Compositions for oral administration of active substances
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) * 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
EP0993831B1 (en) 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9702401D0 (en) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
DE19915272A1 (en) * 1999-04-03 2000-10-05 Vetter & Co Apotheker Syringe for medical purposes comprises a cannula cap which is made of an elastic material and is provided with a well-fitting cavity for the needle carrier
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
AU1189301A (en) 1999-10-29 2001-05-14 Eli Lilly And Company A pharmaceutical composition having high cell membrane permeability
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
MXPA03011027A (en) 2001-06-01 2004-03-19 Novartis Ag Orally administering parathyroid hormone and calcitonin.
RU2322256C2 (en) * 2001-08-17 2008-04-20 Новартис Аг 5-cnac as agent for oral delivery of parathyroid hormone fragments
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone

Also Published As

Publication number Publication date
KR20120065429A (en) 2012-06-20
SK14752003A3 (en) 2004-06-08
KR101320817B1 (en) 2013-10-21
HUP0400120A3 (en) 2012-09-28
ES2282436T3 (en) 2007-10-16
ZA200308625B (en) 2004-07-13
HU229613B1 (en) 2014-03-28
NZ529439A (en) 2005-11-25
EP1397156B1 (en) 2007-03-14
KR20090116836A (en) 2009-11-11
ECSP034858A (en) 2004-01-28
NO330093B1 (en) 2011-02-14
MXPA03011027A (en) 2004-03-19
CN1512892A (en) 2004-07-14
NO20035133L (en) 2003-11-18
IL158777A (en) 2012-06-28
RU2003136733A (en) 2005-05-20
US20080119411A1 (en) 2008-05-22
SK287697B6 (en) 2011-06-06
NO20035133D0 (en) 2003-11-18
AU2006225157B2 (en) 2009-04-23
CZ20033232A3 (en) 2004-06-16
CO5540323A2 (en) 2005-07-29
PT1397156E (en) 2007-05-31
DE60218842T2 (en) 2007-12-20
EP1397156A2 (en) 2004-03-17
WO2002098453A2 (en) 2002-12-12
US8153587B2 (en) 2012-04-10
PL211976B1 (en) 2012-07-31
ATE356631T1 (en) 2007-04-15
CZ307145B6 (en) 2018-02-07
JP2005500277A (en) 2005-01-06
PL364089A1 (en) 2004-12-13
CN101837120A (en) 2010-09-22
AU2006225157A1 (en) 2006-10-19
US20040186050A1 (en) 2004-09-23
JP5073153B2 (en) 2012-11-14
BRPI0209748B1 (en) 2015-11-24
HUP0400120A2 (en) 2005-04-28
RU2300392C2 (en) 2007-06-10
CA2446929A1 (en) 2002-12-12
BR0209748A (en) 2004-07-27
KR20040007617A (en) 2004-01-24
DE60218842D1 (en) 2007-04-26
AU2002344371B2 (en) 2006-06-29
IL158777A0 (en) 2004-05-12
WO2002098453A3 (en) 2003-07-31
JP2010189423A (en) 2010-09-02

Similar Documents

Publication Publication Date Title
US8153587B2 (en) Orally administering parathyroid hormone and calcitonin
US9272040B2 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments
US20090264368A1 (en) Compositions for delivering parathyroid hormone and calcitonin
AU2002344371A1 (en) Orally administering parathyroid hormone and calcitonin
AU2002333443A1 (en) 5-CNAC as oral delivery agent for parathyroid hormone fragments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190531